key: cord-0691625-zq4ty9rw authors: Gaebler, C.; DaSilva, J.; Bednarski, E.; Muecksch, F.; Schmidt, F.; Weisblum, Y.; Millard, K.; Turroja, M.; Cho, A.; Wang, Z.; Caskey, M.; Nussenzweig, M. C.; Bieniasz, P.; Hatziioannou, T. title: SARS-CoV-2 neutralization after mRNA vaccination and variant breakthrough infection date: 2022-02-11 journal: nan DOI: 10.1101/2022.02.09.22270692 sha: 4b0087d1da2e22b40d12f73e7d31419c8ba90a64 doc_id: 691625 cord_uid: zq4ty9rw Vaccination and infection by viral variants are shaping population immunity to SARS-CoV-21 and breakthrough infections of vaccinated or previously infected individuals have become common as variants evade preexisting immunity. Omicron (B.1.1.529) is highly resistant to plasma neutralizing antibodies elicited by infection with prior variants and the 2-dose mRNA vaccination regimens. However, vaccination after infection or a third mRNA vaccine dose elicit high levels of neutralizing antibodies that can also neutralize omicron to a degree2-4. We compared neutralizing antibody titers in 54 individuals that had received 2 or 3 doses of mRNA vaccines and had experienced breakthrough infection with SARS-CoV-2 variants. We compared neutralizing antibody titers in 54 individuals that had received 2 or 3 doses of mRNA vaccines and had experienced breakthrough infection with SARS-CoV-2 variants. Breakthrough variants were deduced based on the prevalent variant circulating in New York City at the time of infection (Fig 1A, S1 and Supplementary appendix). Delta (B.1.617), was the predominant variant from July to early December 2021 but was rapidly displaced by omicron by January 2022 (Fig. 1A) . As a consequence of evolving vaccination recommendations, 24 participants that experienced breakthrough infection with delta had received 2 vaccine doses. Conversely, most omicron breakthrough infections (24 out of 30) were in participants who received 3 vaccine doses. Compared to uninfected 2 dose vaccine recipients, participants with pre-omicron breakthrough infections had median plasma neutralization titers that were 2.8-, 4.9-and 26.4-times greater against Wuhan-hu-1, delta and omicron (all p≤0.0005) (Fig. 1B) . Compared to 3 dose vaccine recipients, participants with omicron breakthrough had neutralizing titers that were 2.9-times greater (p<0.0001) against omicron and 1.4-times greater (p=0.0088) against delta and were not greater against Wuhan-hu-1 (Fig. 1B) . For the few individuals with omicron breakthrough after only 2 vaccine doses, median neutralizing titers were 4.2-, 7.4-and 161.5-times greater against Wuhan-hu-1, delta and omicron (all p≤0.0074) than uninfected 2 dose recipients. Overall, in comparing vaccine doses and breakthrough infections, omicron breakthrough infection elicited the greatest increase in neutralizing antibody titers against omicron itself, but the magnitude of this effect was small in individuals that had received a third vaccine dose. Because omicron breakthrough infection broadened plasma neutralizing activity more effectively than delta variant . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted February 11, 2022. ; https://doi.org/10.1101/2022.02.09.22270692 doi: medRxiv preprint infection (Fig. 1B) , our data suggest that an omicron specific booster shot may have similar effects in those that received only 2 mRNA vaccine doses 5 . In individuals that have already received a third dose of the currently available mRNA vaccines, omicron specific boosters may modestly improve neutralizing responses against omicron while not significantly impacting neutralization of other variants. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 11, 2022. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Uninfected vaccine recipient participants have been previously desrcibed 1 . Heparinized plasma and serum samples were aliquoted and stored at -20 °C or below. Before experiments, aliquots of plasma samples were heat inactivated (56 °C for 1 h) and then stored at 4 °C. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 11, 2022. ; https://doi.org/10.1101/2022.02.09.22270692 doi: medRxiv preprint SARS-CoV-2 pseudotyped particles were generated as previously described 2 . Briefly, 293Tcells were transfected with pNL4-3ΔEnv-nanoluc and pSARS-CoV All spike proteins used in the pseudotype neutralization assays had a 19 amino acid C-terminal deletion and included the R683G substitution, which disrupts the furin cleavage site and increases particle infectivity without grossly affecting antibody sensitivity. Fivefold serially diluted plasmas from vaccinated individuals were incubated with SARS-CoV-2 pseudotyped virus for 1 h at 37 °C. The mixture was subsequently added to an HT1080-based cell line engineered to express human ACE2 (HT1080.ACE2 cl14). The starting serum dilution on cells was 1:50. Nanoluc Luciferase activity in lysates was measured 48 hours post-inoculation using the Nano-Glo Luciferase Assay System (Promega) with the Glomax Navigator (Promega). CoV-2 pseudotyped virus in the absence of serum. The half-maximal neutralization titers for sera . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 11, 2022. ; https://doi.org/10.1101/2022.02.09.22270692 doi: medRxiv preprint (NT50) were determined using four-parameter nonlinear regression (least squares regression method without weighting; constraints: top=1, bottom=0) (GraphPad Prism) and median values calculated for each sample from 2-3 independent experiments. Group comparisons were performed using Mann-Whitney test (GraphPad Prism). The time between diagnosis of infection and sample collection did not significantly affect NT50 values (Fig. S1 ). . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 11, 2022. ; https://doi.org/10.1101/2022.02.09.22270692 doi: medRxiv preprint Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection Plasma Neutralization of the SARS-CoV-2 Omicron Variant. The New England journal of medicine 2021 Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization Considerable escape of SARS-CoV-2 Omicron to antibody neutralization Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern The New England journal of medicine 2021 Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses We are grateful to all participants that volunteered for this study. We thank M. Bergh, M. Okawa . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted February 11, 2022. ; https://doi.org/10.1101/2022.02.09.22270692 doi: medRxiv preprint